What moved Idorsia stock today?

The company reported FY2025 results: revenue rose to CHF 221m from CHF 113m, Quviviq sales reached CHF 134m, and losses narrowed to CHF -112m net and CHF -33m operating. Shares were little changed near CHF 3.75 as investors weighed better results against cautious 2026 guidance.

What were the highlights of Idorsia earnings 2025?

Top line doubled to CHF 221m, led by CHF 134m in Quviviq sales. The net loss narrowed to CHF -112m and the operating loss to CHF -33m, reflecting cost reductions. Management emphasized focus on core assets and disciplined spending to support commercial execution.

What is included in Idorsia 2026 guidance?

Management targets CHF 200m in Quviviq sales in 2026 but still expects an operating loss of about CHF -160m as restructuring continues under the new CEO. The outlook highlights the need for stronger prescription growth and ongoing cost control to move toward break-even.

How important are Quviviq sales for Idorsia stock?

Quviviq is the main revenue driver, delivering CHF 134m in 2025. Hitting the 2026 target of CHF 200m would support sentiment and help absorb fixed costs. Investors should watch prescription growth, refill rates, and reimbursement updates to gauge progress each quarter.

What are key risks for Swiss investors to consider?

Execution risk on Quviviq growth, competitive pressure, and pricing remain central. Guidance still points to a sizeable operating loss in 2026, which keeps funding and cash discipline in focus. Any slowdown in prescriptions or delays in cost savings could weigh on the shares.

Global Market Insights

IDIA.SW Stock Today: FY2025 Revenue Doubles; Loss Narrows — February 26

ByHuzaifa Zahoor February 26, 2026February 26, 2026

Idorsia stock drew Swiss investor attention on 26 February as the biotech reported FY2025 results. Swiss biotech Idorsia (IDIA.SW) doubled revenue to CHF 221m from CHF 113m, with Quviviq sales at CHF 134m. Net loss narrowed to CHF -112m and operating loss to CHF -33m. Shares were little changed near CHF 3.75. Management outlined Idorsia 2026 guidance, aiming for CHF 200m Quviviq sales while still expecting about CHF -160m in operating loss during ongoing restructuring under new CEO Srishti Gupta.